Protalix BioTherapeutics Highlights Rare Disease Drug Pipeline and New Gout Therapy in Latest Corporate Presentation
Reuters
Oct 17
Protalix BioTherapeutics Highlights Rare Disease Drug Pipeline and New Gout Therapy in Latest Corporate Presentation
Protalix BioTherapeutics Inc. has released a corporate presentation detailing its current pipeline and financial status. The company reported $53 million in revenue for the full year 2024 and $25.4 million in revenue from product sales in the first half of 2025. As of June 30, 2025, Protalix holds $33.4 million in cash with no debt or warrants, supporting its operations and pipeline development into 2027. Protalix highlighted its commercial portfolio, which includes approved enzyme replacement therapies for Fabry disease and Gaucher disease in the United States, European Union, and additional markets. The development portfolio features PRX-115, a PEGylated uricase candidate targeting uncontrolled gout, with a Phase 2 trial expected to begin in the fourth quarter of 2025. The company is also advancing PRX-119, a long-acting DNase I, and is pursuing additional programs in rare renal and NETs-related diseases. Over the next three years, Protalix aims to expand its pipeline to five to seven programs spanning discovery to clinical stages. You can access the full presentation through the link below.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Protalix BioTherapeutics Inc. published the original content used to generate this news brief on October 17, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.